BeautyHealth Appoints Philippe Schaison, PharmaD, to Board of Directors

BeautyHealth Appoints Philippe Schaison, PharmaD, to Board of Directors Global Aesthetics Leader Brings Deep Industry Expertise and Proven Track Record Driving Growth Across Health, Beauty, and Consumer Sectors GlobeNewswire November 03, 2025 LONG BEACH, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) — The BeautyHealth Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced the appointment […]

Regeneron Announces Investor Conference Presentations

Regeneron Announces Investor Conference Presentations GlobeNewswire November 03, 2025 TARRYTOWN, N.Y., Nov. 03, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: Jefferies London Healthcare Conference at 3:30 p.m. GMT (10:30 a.m. ET) on Monday, November 17, 2025 7th Annual Wolfe Research Healthcare Conference at 9:20 a.m. ET on

InnovAge Appoints Dr. Paul Taheri as Chief Medical Officer

InnovAge Appoints Dr. Paul Taheri as Chief Medical Officer GlobeNewswire November 03, 2025 DENVER, Nov. 03, 2025 (GLOBE NEWSWIRE) — InnovAge Holding Corp. (“InnovAge” or the “Company”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail, predominantly dual-eligible seniors through the Program of All-inclusive Care for the Elderly (PACE), appoints Paul Taheri,

Levi & Korsinsky Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline – MLTX

Levi & Korsinsky Notifies MoonLake Immunotherapeutics Investors of a Class Action Lawsuit and Upcoming Deadline – MLTX GlobeNewswire November 03, 2025 NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in MoonLake Immunotherapeutics (“MoonLake” or the “Company”) (NASDAQ: MLTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks

Investors who lost money on RCI Hospitality Holdings, Inc. (RICK) should contact Levi & Korsinsky about pending Class Action – RICK

Investors who lost money on RCI Hospitality Holdings, Inc. (RICK) should contact Levi & Korsinsky about pending Class Action – RICK GlobeNewswire November 03, 2025 NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in RCI Hospitality Holdings, Inc. (“RCI Hospitality Holdings, Inc.” or the “Company”) (NASDAQ: RICK) of a

Lost Money on aTyr Pharma, Inc. (ATYR)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

Lost Money on aTyr Pharma, Inc. (ATYR)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky GlobeNewswire November 03, 2025 NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) of a class action securities lawsuit. CLASS DEFINITION: The

Option Care Health to Participate in Upcoming Investor Conferences

Option Care Health to Participate in Upcoming Investor Conferences GlobeNewswire November 03, 2025 BANNOCKBURN, Ill., Nov. 03, 2025 (GLOBE NEWSWIRE) — Option Care Health, Inc. (“Option Care Health”) (Nasdaq: OPCH), the nation's largest independent provider of home and alternate site infusion services, will participate in the following upcoming investor conferences: UBS Global Healthcare Conference, being

Lakeland Fire + Safety Declares Cash Dividend for Fourth Quarter 2026

Lakeland Fire + Safety Declares Cash Dividend for Fourth Quarter 2026 GlobeNewswire November 03, 2025 HUNTSVILLE, Ala., Nov. 03, 2025 (GLOBE NEWSWIRE) — Lakeland Industries, Inc. (“Lakeland Fire + Safety” or “Lakeland”) (NASDAQ: LAKE), a leading global manufacturer of protective clothing and apparel for industry, healthcare and first responders, today announced that its Board of

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis

Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis GlobeNewswire November 03, 2025 Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients

Nyxoah to Participate in the Stifel 2025 Healthcare Conference

Nyxoah to Participate in the Stifel 2025 Healthcare Conference GlobeNewswire November 03, 2025 Nyxoah to Participate in the Stifel 2025 Healthcare Conference Mont-Saint-Guibert, Belgium – November 3, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that

Scroll to Top